Skorpios Trust Amends Stoke Therapeutics Stake

TL;DR

Skorpios Trust updated its Stoke Therapeutics (STOK) filing, watch for ownership changes.

AI Summary

Skorpios Trust, a significant shareholder, filed an amendment (No. 2) to its Schedule 13D on September 23, 2024, regarding its holdings in Stoke Therapeutics, Inc. The filing indicates a change in the beneficial ownership of Stoke Therapeutics' common stock. The specific details of the change in ownership percentage or number of shares were not fully disclosed in the provided header information.

Why It Matters

This filing signals a potential shift in control or influence for Stoke Therapeutics, Inc., as a major shareholder has updated their position. Investors will monitor future filings for details on the nature of this change.

Risk Assessment

Risk Level: medium — Amendments to Schedule 13D filings often indicate significant changes in a major shareholder's position, which can impact stock price and corporate strategy.

Key Numbers

• 2 — Amendment Number (Indicates this is the second update to the filing.)
• 20240923 — Filing Date (Date the amendment was filed with the SEC.)

Key Players & Entities

• Skorpios Trust (company) — Filing entity
• Stoke Therapeutics, Inc. (company) — Subject company
• Patrik Blochlinger (person) — Authorized contact
• Rigmora (Switzerland) Ltd (company) — Associated entity

FAQ

Key Financial Figures

• $0.0001 — , Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of
• $14.05 — n open market transaction at a price of $14.05 per share. Item 5. Interest in Securit

Filing Documents

• stoke13d.htm (SC 13D/A) — 339KB
• 0001123292-24-000282.txt ( ) — 341KB

Purpose of Transaction

Item 4. Purpose of Transaction

is hereby amended and supplemented by adding the following

Item 4 is hereby amended and supplemented by adding the following: On September 19, 2024, Blue Horizon sold 1,937,500 Shares of the Issuer in an open market transaction at a price of $14.05 per share.

Interest in Securities of the Issuer

Item 5. Interest in Securities of the Issuer Items 5(a) - (c) of this Schedule 13D is hereby amended and restated as follows: (a) The responses of the Reporting Persons to rows (7) through (13) of the cover pages of this Schedule 13D are incorporated herein by reference. (b) The responses of the Reporting Persons to rows (7) through (13) of the cover pages of this Schedule 13D are incorporated herein by reference. (c) The information reported in Item 4 is incorporated herein by reference. Other than as disclosed in that item, no transactions in the Shares have been effected by the Reporting Person during the past sixty (60) days.

Materials to be Filed as Exhibits

Item 7. Materials to be Filed as Exhibits

of the Schedule 13D is hereby amended and supplemented as follows

Item 7 of the Schedule 13D is hereby amended and supplemented as follows: Exhibit Number Description 1 Joint Filing Agreement, dated as of September 23, 2024, by and among the Reporting Persons. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dates: September 23, 2024 Blue Horizon Enterprise Ltd. By: /s/ Eleni Constantinou Kyriacou Name: Eleni Constantinou Kyriacou Title: Director Ezbon International Limited By: /s/ Eleni Constantinou Kyriacou Name: Eleni Constantinou Kyriacou Title: Director Montrago Trustees Limited By: /s/ Androulla Papadopoulou Name: Androulla Papadopoulou Title: Director Skorpios Trust By: /s/ Androulla Papadopoulou Name: Androulla Papadopoulou Title: Director Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree as follows: (i) Each of them is individually eligible to use the Schedule 13D to which this Exhibit is attached, and such Schedule 13D is filed on behalf of each of them; and (ii) Each of them is responsible for the timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate. Date: September 23, 2024 Blue Horizon Enterprise Ltd. By: /s/ Eleni Constantinou Kyriacou Name: Eleni Constantinou Kyriacou Title: Director Ezbon International Limited By: /s/ Eleni Constantinou Kyriacou Name: Eleni Constantinou Kyriacou Title: Director Montrago Trustees Limited By: /s/ Androulla Papadopoulou Name: Androulla Papadopoulou Title: Director Skorpios Trust By: /s/ Androulla Papadopoulou Name: Androulla Papadopoulou Title: Director

View Full Filing

View this SC 13D/A filing on SEC EDGAR